Prognostic role of copeptin with all-cause mortality after heart failure: a systematic review and meta-analysis

Abstract

BackgroundAs the C-terminal section of vasopressin precursor, copeptin has been recently suggested as a new prognostic biomarker after heart failure (HF). Thus, the aim of this study was to evaluate the prognostic value of plasma copeptin level with all-cause mortality in patients with HF.MethodsComprehensive strategies were used to search relevant studies from electronic databases. Pooled hazard ratios (HRs) and standardized mean differences (SMDs) together with their 95% confidence intervals (CIs) were calculated. Subgroup analysis and sensitivity analysis were performed to find the potential sources of heterogeneity.ResultsA total of 5,989 participants from 17 prospective studies were included in this meta-analysis. A significant association was observed between circulating copeptin levels and risk of all-cause mortality in patients with HF (categorical copeptin: HR =1.69, 95% CI =1.42–2.01; per unit copeptin: HR =1.03, 95% CI =1.00–1.07; log unit copeptin: HR =3.26, 95% CI =0.95–11.25). Pooled SMD showed that copeptin levels were significantly higher in patients with HF who died during the follow-up period than in survivors (SMD =1.19, 95% CI =0.81–1.57). Subgroup analyses also confirmed this significant association, while sensitivity analyses indicated that the overall results were stable.ConclusionThis study demonstrated that circulating copeptin seemed to be a novel biomarker to provide better prediction of all-cause mortality in patients with HF.

Effect of exercise therapy on established and emerging circulating biomarkers in patients with heart failure: a systematic review and meta-analysis

“…sST2, a member of the interleukin (IL)-1 receptor family and defined as a ligand for IL-33, is considered a cardiovascular stress protein, associated with fibrosis, cardiac and vascular remodelling and inflammation 72. Initial evidence also indicates that other novel biomarkers, such as CT-proAVP20 73 74 and MR-proADM,75 both biomarkers of neurohormonal activation, also have prognostic value in HF.…”

“…In fact, the combination of the gold standard cardiac biomarkers of BNP/NT-proBNP with the newer biomarkers, such as soluble ST2 (sST2) and Gal-3, may improve risk stratification and prognosis 10 11. Other emerging biomarkers, mid-regional atrial natriuretic peptide (MR-proANP), mid-regional adrenomedullin (MR-proADM) and copeptin (CT-proAVP), have also been shown to have prognostic value in HF 9 20…”

Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure Decompensation

“…По сути копептин является суррогатным маркером AVP, выгодно отличаясь от последнего чрез- ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ § вычайной стабильностью даже при комнатной температуре [38,39], что обеспечивает легкость и точность его определения стандартным иммуноферментным методом. Большинство проведенных клинических испытаний, а также опубликованные недавно результаты мета-анализа свидетельствуют о возможности и целесообразности использования копептина для стратификации риска и оценки кратко-и долгосрочного прогноза у больных с ХСН [40]. A. Gegenhuber и соавт.…”

Aquaporins and diseases pathogenesis: From trivial to undeniable involvements, a disease‐based point of view

“…There are some studies that proposed Copeptin (C-terminal pro-Arginine-Vasopressin) as an independent prognostic factor and a risk predictor of heart failure with the reduced EF (Balling et al, 2012;W. L. Miller et al, 2013;Pozsonyi et al, 2015;P. Zhang et al, 2017).…”